Mankind Pharma

Mankind Pharma Assets per Share

The Total Assets per Share of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 680.20 INR. In the previous year, Total Assets per Share was 672.45 INR — a change of 1.15% (higher).

Assets per Share

680.20INR

YoY

1.15%

Last updated:

Total Assets per Share of Mankind Pharma is 2026 680.20 INR. Total Assets per Share of Mankind Pharma was 2025 672.45 INR. It decreases by 1.15% higher compared to the previous year.

The Mankind Pharma Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2019
99.62 INR
Jan 1, 2020
122.90 INR
Jan 1, 2021
154.37 INR
Jan 1, 2022
221.60 INR
Jan 1, 2023
235.35 INR
Jan 1, 2024
289.80 INR
Jan 1, 2025
672.45 INR
Jan 1, 2026
680.20 INR
The Mankind Pharma Assets per Share history
YEARAssets per ShareYoY
680.20INR+1.15%
672.45INR+132.04%
289.80INR+23.14%
235.35INR+6.21%
221.60INR+43.55%
154.37INR+25.61%
122.90INR+23.36%
99.62INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Total Assets per Share of Mankind Pharma is 680.20 INR in 2026.

Total Assets per Share of Mankind Pharma changed from 672.45 INR to 680.20 INR, representing a 1.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Mankind Pharma

All Key Metrics — Mankind Pharma